NCT05216575View on ClinicalTrials.gov

Almitrine in COVID-19 Patients With ARDS Treated by HFNO

CompletedOBSERVATIONAL
Enrollment

62

Participants

Timeline

Start Date

January 1, 2021

Primary Completion Date

January 31, 2022

Study Completion Date

January 31, 2022

Conditions
ARDSHypoxemia
Interventions
DRUG

Administration of Almitrine

Administration of Almitrine (intravenous bolus of 0.5 mg/kg over 30 minutes followed by a continuous perfusion of 16 mg/kg/min in responders)

Trial Locations (1)

06200

CHU de NICE, Nice

All Listed Sponsors
lead

Centre Hospitalier Universitaire de Nice

OTHER

NCT05216575 - Almitrine in COVID-19 Patients With ARDS Treated by HFNO | Biotech Hunter | Biotech Hunter